CA2717511A1 - Modulation de la structure, de l'activite et/ou du taux d'expression d'une enzyme - Google Patents
Modulation de la structure, de l'activite et/ou du taux d'expression d'une enzyme Download PDFInfo
- Publication number
- CA2717511A1 CA2717511A1 CA2717511A CA2717511A CA2717511A1 CA 2717511 A1 CA2717511 A1 CA 2717511A1 CA 2717511 A CA2717511 A CA 2717511A CA 2717511 A CA2717511 A CA 2717511A CA 2717511 A1 CA2717511 A1 CA 2717511A1
- Authority
- CA
- Canada
- Prior art keywords
- modulator
- activity
- complex
- cells
- pdh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2008/002853 WO2009110859A1 (fr) | 2008-03-04 | 2008-03-04 | Modulation de la structure, de l’activité et/ou du taux d’expression d’une enzyme |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2717511A1 true CA2717511A1 (fr) | 2009-09-11 |
Family
ID=41056265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2717511A Abandoned CA2717511A1 (fr) | 2008-03-04 | 2008-03-04 | Modulation de la structure, de l'activite et/ou du taux d'expression d'une enzyme |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2260019A4 (fr) |
JP (1) | JP2011513395A (fr) |
KR (1) | KR20110004846A (fr) |
CN (1) | CN102089276A (fr) |
AU (1) | AU2008352076A1 (fr) |
BR (1) | BRPI0821176A2 (fr) |
CA (1) | CA2717511A1 (fr) |
IL (1) | IL207943A0 (fr) |
MX (1) | MX2010009673A (fr) |
WO (1) | WO2009110859A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263653B2 (en) * | 2007-04-18 | 2012-09-11 | Cornerstone Pharmaceuticals, Inc. | Pharmaceutical formulations containing lipoic acid derivatives |
BRPI0821894A2 (pt) * | 2008-04-04 | 2015-07-21 | Robert Shorr | Modulador do estado de fosforilação farmaceuticamente aceitável de pelo menos uma enzima e/ou complexo enzimático, ou subunidades das mesma, nas mitocôndrias de células doentes de animais de sangue quente, incluindo seres humanos, método de modulação de pelo menos uma enzima ou um complexo enzimático, ou uma subunidade dos mesmos, em um paciente que apresenta uma doença, uma condição, ou uma síndrome que inclui uma alteração do estado de fosforilação, de pelo menos uma enzima e/ou um complexo enzimático, ou uma subunidade das mesmas, e método para diagnosticar e prever o benefício em um paciente que apresenta sintomas de uma doença, uma condição, ou uma síndrome que incluem uma alteração do estado de fosforilação, de pelo menos uma enzima e/ou complexo enzimático, ou uma subunidade dos mesmos |
WO2015195071A1 (fr) | 2014-06-19 | 2015-12-23 | Robert Shorr | Composés pharmaceutiques |
AU2014398232B2 (en) | 2014-06-19 | 2019-11-28 | Rafael Pharmaceuticals, Inc. | Pharmaceutical compounds |
US20220040133A1 (en) * | 2018-12-20 | 2022-02-10 | Rafael Pharmaceuticals, Inc. | Oral therapy using 6,8-bis-benzylthio-octanoic acid |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5463093A (en) * | 1993-11-26 | 1995-10-31 | Garnett; Merrill | Palladium complexes and methods for using same in the treatment of tumors or Psoriasis |
DE4343593C2 (de) * | 1993-12-21 | 1998-05-20 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz |
ES2340488T3 (es) * | 1998-10-26 | 2010-06-04 | The Research Foundation Of State University Of New York | Sales derivadas del acido lipoico y su utilizacion para el tratamiento de las enfermedades. |
US6284786B1 (en) * | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
IT1312060B1 (it) * | 1999-04-09 | 2002-04-04 | Antibioticos Spa | Uso dell'acido alfa lipoico nel trattamento antimetastatico. |
EP1172110A3 (fr) * | 2000-07-07 | 2003-09-17 | Basf Aktiengesellschaft | Utilisation de l'acide lipoique pour augmenter la biodisponibilité de sels minéraux |
US20020071234A1 (en) * | 2000-10-25 | 2002-06-13 | George Alexanian | Battery powered programmable remote switch controller |
WO2006119355A2 (fr) * | 2005-05-03 | 2006-11-09 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation hypothalamique du metabolisme du glucose chez les mammiferes par l'intermediaire de nutriments |
JP5480804B2 (ja) * | 2007-04-18 | 2014-04-23 | コーナーストーン ファーマシューティカルズ,インコーポレーテッド | リポ酸誘導体を含有する医薬製剤 |
EP2695614B1 (fr) * | 2007-04-18 | 2017-07-05 | Cornerstone Pharmaceuticals, Inc. | Dérivés d'acide lipoïque |
-
2008
- 2008-03-04 BR BRPI0821176A patent/BRPI0821176A2/pt not_active IP Right Cessation
- 2008-03-04 MX MX2010009673A patent/MX2010009673A/es unknown
- 2008-03-04 CN CN2008801288127A patent/CN102089276A/zh active Pending
- 2008-03-04 WO PCT/US2008/002853 patent/WO2009110859A1/fr active Application Filing
- 2008-03-04 JP JP2010549618A patent/JP2011513395A/ja active Pending
- 2008-03-04 KR KR1020107022085A patent/KR20110004846A/ko not_active Application Discontinuation
- 2008-03-04 AU AU2008352076A patent/AU2008352076A1/en not_active Abandoned
- 2008-03-04 EP EP08726395A patent/EP2260019A4/fr not_active Withdrawn
- 2008-03-04 CA CA2717511A patent/CA2717511A1/fr not_active Abandoned
-
2010
- 2010-09-02 IL IL207943A patent/IL207943A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2260019A4 (fr) | 2011-08-03 |
KR20110004846A (ko) | 2011-01-14 |
BRPI0821176A2 (pt) | 2015-10-06 |
AU2008352076A1 (en) | 2009-09-11 |
CN102089276A (zh) | 2011-06-08 |
WO2009110859A1 (fr) | 2009-09-11 |
IL207943A0 (en) | 2010-12-30 |
EP2260019A1 (fr) | 2010-12-15 |
JP2011513395A (ja) | 2011-04-28 |
MX2010009673A (es) | 2011-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hashemi et al. | Cytotoxic effects of intra and extracellular zinc chelation on human breast cancer cells | |
CA2720396A1 (fr) | Composition pharmaceutique | |
Gan et al. | Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity | |
CA2638735A1 (fr) | Procedes permettant d'identifier les inhibiteurs de reponse aux proteines depliees | |
An et al. | Synthesis and biological evaluation of selenium-containing 4-anilinoquinazoline derivatives as novel antimitotic agents | |
JP2014512337A (ja) | スチルベン類似体およびがんを処置する方法 | |
Sandoval-Acuña et al. | Destabilization of mitochondrial functions as a target against breast cancer progression: Role of TPP+-linked-polyhydroxybenzoates | |
Lee et al. | 15-Keto prostaglandin E2 suppresses STAT3 signaling and inhibits breast cancer cell growth and progression | |
CA2717511A1 (fr) | Modulation de la structure, de l'activite et/ou du taux d'expression d'une enzyme | |
Liu et al. | Tumor killing by a dietary curcumin mono-carbonyl analog that works as a selective ROS generator via TrxR inhibition | |
Li et al. | Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations | |
EP3189033B1 (fr) | Composés pharmaceutiques | |
US20180273551A1 (en) | Pharmaceutical compounds | |
CA2829654C (fr) | Petites molecules remplacant ou faisant disparaitre la fonction p53 | |
US20190119309A1 (en) | Pharmaceutical compounds | |
Lee et al. | Concurrent induction of apoptosis and necroptosis in apigenin‑treated malignant mesothelioma cells: Reversal of Warburg effect through Akt inhibition and p53 upregulation | |
Oh et al. | Selective targeting of cancer cells using a hydrogen peroxide-activated Hsp90 inhibitor | |
WO2010110887A1 (fr) | Acides gras | |
JP2010527328A (ja) | 金属トリアングロ化合物およびその使用方法 | |
US20240239787A1 (en) | Compounds for use in the treatment of cancer | |
US11352382B2 (en) | Mito-lonidamine, compositions and methods of use | |
Zhou et al. | Structural Optimization of Marine Natural Product Pretrichodermamide B for the Treatment of Colon Cancer by Targeting the JAK/STAT3 Signaling Pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130304 |
|
FZDE | Discontinued |
Effective date: 20150929 |